Chikungunya-Pipeline Review, H1 2015

Chikungunya-Pipeline Review, H1 2015

  • Products Id :- GMDHC6543IDB
  • |
  • Pages: 75
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Chikungunya-Pipeline Review, H1 2015


Global Markets Direct's, 'Chikungunya-Pipeline Review, H1 2015', provides an overview of the Chikungunya's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Chikungunya, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chikungunya and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Chikungunya

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Chikungunya and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Chikungunya products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Chikungunya pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Chikungunya

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Chikungunya pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Chikungunya Overview 9

Therapeutics Development 10

Pipeline Products for Chikungunya-Overview 10

Pipeline Products for Chikungunya-Comparative Analysis 11

Chikungunya-Therapeutics under Development by Companies 12

Chikungunya-Therapeutics under Investigation by Universities/Institutes 13

Chikungunya-Pipeline Products Glance 14

Clinical Stage Products 14

Early Stage Products 15

Unknown Stage Products 16

Chikungunya-Products under Development by Companies 17

Chikungunya-Products under Investigation by Universities/Institutes 18

Chikungunya-Companies Involved in Therapeutics Development 19

Abivax S.A. 19

Arbovax, Inc. 20

Bharat Biotech International Limited 21

Indian Immunologicals Limited 22

Inovio Pharmaceuticals, Inc. 23

Integral Molecular, Inc. 24

Merck & Co., Inc. 25

PaxVax 26

Profectus BioSciences, Inc. 27

Takeda Pharmaceutical Company Limited 28

Themis Bioscience GmbH 29

Chikungunya-Therapeutics Assessment 30

Assessment by Monotherapy Products 30

Assessment by Target 31

Assessment by Mechanism of Action 33

Assessment by Route of Administration 35

Assessment by Molecule Type 37

Drug Profiles 39

ABX-309-Drug Profile 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

Antibody for Chikungunya-Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

chikungunya vaccine-Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

chikungunya vaccine-Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

chikungunya vaccine-Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

chikungunya vaccine-Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

chikungunya vaccine-Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

chikungunya vaccine-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

chikungunya vaccine-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

chikungunya vaccine-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

chikungunya vaccine-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

chikungunya vaccine-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

chikungunya vaccine-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

chikungunya vaccine-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

chikungunya vaccine-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

chikungunya vaccine-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

DEF-201-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

IMCKV-063-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

Monoclonal Antibodies for Chikungunya-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

Monoclonal Antibodies to Inhibit CHIKV E2 for Chikungunya-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

Monoclonal Antibodies to Inhibit Viral E1/E2 Proteins for Chikungunya-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

MV-CHIK-Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

Small Molecule to Inhibit NS2 and NS3 for Chikungunya-Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

Small Molecules to Inhibit Viral RNA for Chikungunya Virus Infections-Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

Chikungunya-Recent Pipeline Updates 65

Chikungunya-Dormant Projects 67

Chikungunya-Product Development Milestones 68

Featured News & Press Releases 68

Mar 02, 2015: Themis Bioscience's Chikungunya Vaccine Study Results Published in The Lancet Infectious Diseases 68

Nov 20, 2014: Themis Bioscience's Vaccine Against Chikunguya Successful In Phase 1 68

Aug 14, 2014: Experimental chikungunya vaccine induces robust antibody response 69

Jun 12, 2014: Threat of Emerging Virus can be Stopped: Interim results of First Clinical Trial of Themis Bioscience's Vaccine Candidate Against Chikungunya Fever Prove Successful 71

Mar 27, 2013: Themis Bioscience Plans To Initiate Phase I Study Of Chikungunya Fever Vaccine Candidate 71

Dec 20, 2011: NIAID Enrolls Participants In Chikungunya Vaccine Trial 72

Aug 15, 2011: Inviragen And University of Texas Medical Branch Receive Funding For Development Of Chikungunya Virus Vaccine 72

Nov 04, 2010: Novel Recombinant Chikungunya Virus Vaccine Shown To Be Safe And Effective In Multiple Animal Models 73

Nov 02, 2010: Inviragen Receives Two Therapeutic Discovery Project Grants For Vaccine Development 73

Appendix 74

Methodology 74

Coverage 74

Secondary Research 74

Primary Research 74

Expert Panel Validation 74

Contact Us 74

Disclaimer 75

List of Tables

Number of Products under Development for Chikungunya, H1 2015 10

Number of Products under Development for Chikungunya-Comparative Analysis, H1 2015 11

Number of Products under Development by Companies, H1 2015 12

Number of Products under Investigation by Universities/Institutes, H1 2015 13

Comparative Analysis by Clinical Stage Development, H1 2015 14

Comparative Analysis by Early Stage Development, H1 2015 15

Comparative Analysis by Unknown Stage Development, H1 2015 16

Products under Development by Companies, H1 2015 17

Products under Investigation by Universities/Institutes, H1 2015 18

Chikungunya-Pipeline by Abivax S.A., H1 2015 19

Chikungunya-Pipeline by Arbovax, Inc., H1 2015 20

Chikungunya-Pipeline by Bharat Biotech International Limited, H1 2015 21

Chikungunya-Pipeline by Indian Immunologicals Limited, H1 2015 22

Chikungunya-Pipeline by Inovio Pharmaceuticals, Inc., H1 2015 23

Chikungunya-Pipeline by Integral Molecular, Inc., H1 2015 24

Chikungunya-Pipeline by Merck & Co., Inc., H1 2015 25

Chikungunya-Pipeline by PaxVax, H1 2015 26

Chikungunya-Pipeline by Profectus BioSciences, Inc., H1 2015 27

Chikungunya-Pipeline by Takeda Pharmaceutical Company Limited, H1 2015 28

Chikungunya-Pipeline by Themis Bioscience GmbH, H1 2015 29

Assessment by Monotherapy Products, H1 2015 30

Number of Products by Stage and Target, H1 2015 32

Number of Products by Stage and Mechanism of Action, H1 2015 34

Number of Products by Stage and Route of Administration, H1 2015 36

Number of Products by Stage and Molecule Type, H1 2015 38

Chikungunya Therapeutics-Recent Pipeline Updates, H1 2015 65

Chikungunya-Dormant Projects, H1 2015 67

List of Figures

Number of Products under Development for Chikungunya, H1 2015 10

Number of Products under Development for Chikungunya-Comparative Analysis, H1 2015 11

Number of Products under Development by Companies, H1 2015 12

Number of Products under Investigation by Universities/Institutes, H1 2015 13

Comparative Analysis by Clinical Stage Development, H1 2015 14

Comparative Analysis by Early Stage Products, H1 2015 15

Assessment by Monotherapy Products, H1 2015 30

Number of Products by Top 10 Targets, H1 2015 31

Number of Products by Stage and Top 10 Targets, H1 2015 32

Number of Products by Top 10 Mechanism of Actions, H1 2015 33

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 34

Number of Products by Top 10 Routes of Administration, H1 2015 35

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 36

Number of Products by Top 10 Molecule Types, H1 2015 37

Number of Products by Stage and Top 10 Molecule Types, H1 2015 38

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Abivax S.A.

Arbovax, Inc.

Bharat Biotech International Limited

Indian Immunologicals Limited

Inovio Pharmaceuticals, Inc.

Integral Molecular, Inc.

Merck & Co., Inc.


Profectus BioSciences, Inc.

Takeda Pharmaceutical Company Limited

Themis Bioscience GmbH

Chikungunya Therapeutic Products under Development, Key Players in Chikungunya Therapeutics, Chikungunya Pipeline Overview, Chikungunya Pipeline, Chikungunya Pipeline Assessment

select a license

Single User License
USD 2000 INR 136600
Site License
USD 4000 INR 273200
Corporate User License
USD 6000 INR 409800



Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]